Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NEUPHORIA THERAPEUTICS INC (NEUP) Stock Price & Overview
NASDAQ:NEUP • US64136E1029
Current stock price
5.22 USD
-0.05 (-0.95%)
Last:
The current stock price of NEUP is 5.22 USD. Today NEUP is down by -0.95%. In the past month the price increased by 18.37%. In the past year, price increased by 3.26%.
NEUP Key Statistics
52-Week Range3.645 - 21.4004
Current NEUP stock price positioned within its 52-week range.
1-Month Range4.21 - 5.37
Current NEUP stock price positioned within its 1-month range.
- Market Cap
- 28.136M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.12
- Dividend Yield
- N/A
NEUP Stock Performance
Today
-0.95%
1 Week
+3.57%
1 Month
+18.37%
3 Months
+29.85%
Longer-term
6 Months +14.73%
1 Year +3.26%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
NEUP Stock Chart
NEUP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NEUP. When comparing the yearly performance of all stocks, NEUP is one of the better performing stocks in the market, outperforming 71.58% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NEUP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEUP. The financial health of NEUP is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NEUP Earnings
Next Earnings DateMay 18, 2026
Last Earnings DateFeb 17, 2026
PeriodQ2 / 2026
EPS Reported-$0.77
Revenue Reported
EPS Surprise 48.41%
Revenue Surprise %
NEUP Forecast & Estimates
9 analysts have analysed NEUP and the average price target is 9.96 USD. This implies a price increase of 90.84% is expected in the next year compared to the current price of 5.22.
For the next year, analysts expect an EPS growth of -1180.52% and a revenue growth -100% for NEUP
Analysts
Analysts80
Price Target9.96 (90.8%)
EPS Next Y-1180.52%
Revenue Next Year-100%
NEUP Financial Highlights
Over the last trailing twelve months NEUP reported a non-GAAP Earnings per Share(EPS) of -2.12. The EPS decreased by -130% compared to the year before.
Income Statements
Revenue(TTM)15.00M
Net Income(TTM)-5.66M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.48% | ||
| ROE | -19.07% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%133.41%
Sales Q2Q%-100%
EPS 1Y (TTM)-130%
Revenue 1Y (TTM)N/A
NEUP Ownership
Ownership
Inst Owners29.23%
Shares5.39M
Float4.97M
Ins Owners3.41%
Short Float %0.47%
Short Ratio0.44
NEUP Industry Overview
NEUP operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
NEUP Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NEUP
Company Profile
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Company Info
IPO: 1999-12-21
NEUPHORIA THERAPEUTICS INC
100 Summit Dr
Burlington MASSACHUSETTS US
Employees: 8
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What does NEUP do?
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
What is the stock price of NEUPHORIA THERAPEUTICS INC today?
The current stock price of NEUP is 5.22 USD. The price decreased by -0.95% in the last trading session.
Does NEUP stock pay dividends?
NEUP does not pay a dividend.
What is the ChartMill rating of NEUPHORIA THERAPEUTICS INC stock?
NEUP has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does NEUPHORIA THERAPEUTICS INC belong to?
NEUPHORIA THERAPEUTICS INC (NEUP) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for NEUP stock?
NEUPHORIA THERAPEUTICS INC (NEUP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.12).